Mamta Parikh

1.2k total citations
62 papers, 429 citations indexed

About

Mamta Parikh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Mamta Parikh has authored 62 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 15 papers in Surgery. Recurrent topics in Mamta Parikh's work include Prostate Cancer Treatment and Research (29 papers), Bladder and Urothelial Cancer Treatments (14 papers) and PARP inhibition in cancer therapy (12 papers). Mamta Parikh is often cited by papers focused on Prostate Cancer Treatment and Research (29 papers), Bladder and Urothelial Cancer Treatments (14 papers) and PARP inhibition in cancer therapy (12 papers). Mamta Parikh collaborates with scholars based in United States, United Kingdom and Spain. Mamta Parikh's co-authors include Primo N. Lara, Christopher P. Evans, Marc Dall’Era, Jinyi Qi, Allen C. Gao, Guobao Wang, Yasser G. Abdelhafez, Chengfei Liu, Ramsey D. Badawi and Chong-xian Pan and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Journal of Urology.

In The Last Decade

Mamta Parikh

54 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mamta Parikh United States 11 172 167 150 94 59 62 429
Apostolos Menegakis Germany 12 152 0.9× 128 0.8× 199 1.3× 107 1.1× 94 1.6× 16 390
George Horng United States 9 139 0.8× 90 0.5× 130 0.9× 92 1.0× 69 1.2× 12 344
Linda Lam United States 8 131 0.8× 202 1.2× 203 1.4× 113 1.2× 79 1.3× 23 467
Chuanben Chen China 14 235 1.4× 176 1.1× 158 1.1× 53 0.6× 74 1.3× 61 539
Lydia Koi Germany 10 144 0.8× 112 0.7× 154 1.0× 84 0.9× 150 2.5× 19 375
Xianglin Yuan China 11 210 1.2× 187 1.1× 106 0.7× 55 0.6× 25 0.4× 28 439
Elisa De Camilli Italy 14 133 0.8× 86 0.5× 156 1.0× 53 0.6× 126 2.1× 27 447
Veronica Bonasera Italy 5 228 1.3× 73 0.4× 152 1.0× 66 0.7× 44 0.7× 5 375
Sara Chiblak Germany 8 190 1.1× 109 0.7× 141 0.9× 48 0.5× 78 1.3× 12 394

Countries citing papers authored by Mamta Parikh

Since Specialization
Citations

This map shows the geographic impact of Mamta Parikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mamta Parikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mamta Parikh more than expected).

Fields of papers citing papers by Mamta Parikh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mamta Parikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mamta Parikh. The network helps show where Mamta Parikh may publish in the future.

Co-authorship network of co-authors of Mamta Parikh

This figure shows the co-authorship network connecting the top 25 collaborators of Mamta Parikh. A scholar is included among the top collaborators of Mamta Parikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mamta Parikh. Mamta Parikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rathmell, W. Kimryn, Geoffrey I. Shapiro, Naoko Takebe, et al.. (2024). A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2 - Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Research Communications. 4(7). 1793–1801. 6 indexed citations
3.
Ullah, Asmat, Rashmi Verma, Allen C. Gao, et al.. (2024). A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 42(16_suppl). e17027–e17027. 1 indexed citations
4.
5.
Wang, Yiran, Yasser G. Abdelhafez, Benjamin A. Spencer, et al.. (2024). High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET. Journal of Nuclear Medicine. 65(5). 714–721. 4 indexed citations
6.
Wells, Kristina V, et al.. (2023). Prostate cancer and bone: clinical presentation and molecular mechanisms. Endocrine Related Cancer. 30(9). 5 indexed citations
7.
Mar, Nataliya, Kevin Zarrabi, Shuchi Gulati, et al.. (2023). Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. 22(2). 217–223.
8.
Jani, Chinmay, Wanling Xie, Archana Ajmera, et al.. (2023). A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.. Journal of Clinical Oncology. 41(16_suppl). TPS5110–TPS5110.
9.
10.
Siddiqui, Salma, Christopher A. Lucchesi, Benjamin A. Mooso, et al.. (2023). Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer. Scientific Reports. 13(1). 9617–9617. 7 indexed citations
11.
Rathmell, W. Kimryn, Geoffrey I. Shapiro, Jordi Rodón, et al.. (2023). A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.. Journal of Clinical Oncology. 41(16_suppl). 3104–3104. 2 indexed citations
12.
Durbin‐Johnson, Blythe, William T. N. Culp, Carrie A. Palm, et al.. (2022). Untargeted Metabolomics Identify a Panel of Urinary Biomarkers for the Diagnosis of Urothelial Carcinoma of the Bladder, as Compared to Urolithiasis with or without Urinary Tract Infection in Dogs. Metabolites. 12(3). 200–200. 7 indexed citations
13.
Tu, Mei‐Juan, et al.. (2022). ATR Inhibition in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 21(2). 203–207. 4 indexed citations
14.
Parikh, Mamta & Primo N. Lara. (2022). Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. PubMed. 6(2). 105–107.
15.
Parikh, Mamta, Chengfei Liu, Chun‐Yi Wu, et al.. (2021). Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific Reports. 11(1). 6377–6377. 63 indexed citations
16.
Parikh, Mamta. (2021). Clinical Trials Corner: A New Look at Cytoreductive Nephrectomy. 5(2). 113–114. 1 indexed citations
17.
Wang, Guobao, Lorenzo Nardo, Mamta Parikh, et al.. (2021). Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling. Journal of Nuclear Medicine. 63(8). 1274–1281. 70 indexed citations
18.
Wang, Guobao, Mamta Parikh, Lorenzo Nardo, et al.. (2020). Total-Body Dynamic PET of Metastatic Cancer: First Patient Results. 61. 208–208. 6 indexed citations
19.
Parikh, Mamta, et al.. (2018). Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer. Cancer Treatment and Research Communications. 16. 38–44. 3 indexed citations
20.
Parikh, Mamta, Jonathan W. Riess, & Primo N. Lara. (2016). New and emerging developments in extensive-stage small cell lung cancer therapeutics. Current Opinion in Oncology. 28(2). 97–103. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Apostolos Menegakis Breakdown of academic impact, for papers by George Horng Breakdown of academic impact, for papers by Linda Lam Breakdown of academic impact, for papers by Chuanben Chen Breakdown of academic impact, for papers by Lydia Koi Breakdown of academic impact, for papers by Xianglin Yuan Breakdown of academic impact, for papers by Elisa De Camilli Breakdown of academic impact, for papers by Veronica Bonasera Breakdown of academic impact, for papers by Sara Chiblak
Rankless by CCL
2026